Interim Report Archives

Interim Report First Quarter 2024

January–March 2024, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -67,781 thousand (-34,827) Earnings per share before dilution amounted to SEK -2.17 (-1.54) Cash flow from operating activities amounted to SEK -55,311 thousand (-45,535) Cash flow from investing activities amounted to SEK -5,149 thousand (-14,650) Significant events during […]

Interim Report Fourth Quarter 2023

October-December 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -54,513 thousand (-55,220) Earnings per share before dilution amounted to SEK -1.85 (-2.48) Cash flow from operating activities amounted to SEK -32,626 thousand (-35,003) Cash flow from investing activities amounted to SEK -20,729 thousand (-29,481) January-December 2023, Group […]

Interim Report Third Quarter 2023

July-September 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -38,942 thousand (-28,651) Earnings per share before dilution amounted to SEK -1.59 (-1.39) Cash flow from operating activities amounted to SEK -68,611 thousand (-23,091) Cash flow from investing activities amounted to SEK -14,470 thousand (-29,126) January-September 2023, Group […]

Interim Report Second Quarter 2023

April-June 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -51,402 thousand (-28,865) Earnings per share before dilution amounted to SEK -2.27 (-1.40) Cash flow from operating activities amounted to SEK -56,503 thousand (-24,472) Cash flow from investing activities amounted to SEK -16,027 thousand (-29,197) January-June 2023, Group […]

Interim Report First Quarter 2023

January–March 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -34,827 thousand (-18,934) Earnings per share before dilution amounted to SEK -1.54 (-0.92) Cash flow from operating activities amounted to SEK -45,535 thousand (-27,613) Cash flow from investing activities amounted to SEK -14,650 thousand (-47,541) Significant events during […]

Interim Report Fourth Quarter 2022

October–December 2022, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -55,220 thousand (-51,944) Earnings per share before dilution amounted to -2.48 SEK (-2.62) Cash flow from operating activities amounted to SEK -35,003 thousand (-10,280) Cash flow from investing activities amounted to SEK -29,481 thousand (-33,691) January–December 2022, Group […]

Interim Report Third Quarter 2022

Once again an eventful quarter July–September 2022, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -28,651 thousand (-13,890) Earnings per share before dilution amounted to SEK -1.39 (-0.73) Cash flow from operating activities amounted to SEK -23,091 thousand (-16,524) Cash flow from investing activities amounted to SEK -29,126 […]

Interim Report Second Quarter 2022

A vision to improve patients’ lives Second quarter 2022 (April–June), Group· Net sales amounted to SEK 0 thousand (0)· Loss before tax amounted to SEK -28,865 thousand (-16,952)· Earnings per share before dilution amounted to SEK -1.40 (-0.89)· Cash flow from operating activities amounted to SEK -24,472 thousand (-12,831)· Cash flow from investing activities amounted to SEK -29,197 […]

An eventful quarter sets the agenda for an intense 2022

First Quarter 2022 (January 1 – March 31), Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -18,934 thousand (-13,912) Earnings per share before dilution amounted to SEK -0.92 (-0.73) Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971) Cash flow from investing activities amounted to SEK […]

Xspray Pharma publishes Q4 Year-End report 2021

”When looking back at Xspray Pharma’s fourth quarter 2021, I see it marked by hope for the future. After the end of the quarter, we reached a significant milestone when the US Food and Drug Administration (FDA) announced that it had agreed to review Xspray Pharma’s first product candidate: Dasynoc, an improved version of dasatinib. […]